Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes
Status:
Completed
Trial end date:
2004-09-02
Target enrollment:
Participant gender:
Summary
This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety
of repaglinide and Glurenorm® and Glucobay® given as the mono-therapy in Chinese subjects
being treatment-naive type 2 diabetics.